|
Cipla Limited (Cipla.NS) Avaliação DCF
IN | Healthcare | Drug Manufacturers - General | NSE
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Cipla Limited (CIPLA.NS) Bundle
Aprimore suas estratégias de investimento com a calculadora DCF CIPLA LIMITED (CIPLANS)! Utilize dados financeiros CIPLA precisos, ajuste as projeções e despesas de crescimento e visualize instantaneamente como essas mudanças afetam o valor intrínseco da CIPLA Limited (Ciplans).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167,035.8 | 189,968.3 | 216,327.6 | 224,731.8 | 257,740.9 | 287,495.7 | 320,685.6 | 357,707.0 | 399,002.4 | 445,065.1 |
| Revenue Growth, % | 0 | 13.73 | 13.88 | 3.88 | 14.69 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 |
| EBITDA | 34,650.5 | 44,363.5 | 45,722.6 | 51,317.1 | 67,195.1 | 65,628.9 | 73,205.4 | 81,656.6 | 91,083.4 | 101,598.5 |
| EBITDA, % | 20.74 | 23.35 | 21.14 | 22.83 | 26.07 | 22.83 | 22.83 | 22.83 | 22.83 | 22.83 |
| Depreciation | 10,973.1 | 10,005.7 | 9,878.3 | 10,178.3 | 9,416.1 | 14,136.2 | 15,768.2 | 17,588.5 | 19,619.0 | 21,884.0 |
| Depreciation, % | 6.57 | 5.27 | 4.57 | 4.53 | 3.65 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 |
| EBIT | 23,677.4 | 34,357.8 | 35,844.3 | 41,138.8 | 57,779.0 | 51,492.7 | 57,437.2 | 64,068.0 | 71,464.3 | 79,714.5 |
| EBIT, % | 14.18 | 18.09 | 16.57 | 18.31 | 22.42 | 17.91 | 17.91 | 17.91 | 17.91 | 17.91 |
| Total Cash | 17,589.0 | 31,532.0 | 46,316.7 | 67,350.5 | 77,790.0 | 62,495.7 | 69,710.5 | 77,758.2 | 86,735.0 | 96,748.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 42,260.7 | 36,193.4 | 36,049.8 | 40,570.0 | 47,706.6 | 56,107.3 | 62,584.6 | 69,809.6 | 77,868.8 | 86,858.3 |
| Account Receivables, % | 25.3 | 19.05 | 16.66 | 18.05 | 18.51 | 19.52 | 19.52 | 19.52 | 19.52 | 19.52 |
| Inventories | 43,776.0 | 46,691.8 | 53,502.4 | 51,564.3 | 52,379.5 | 68,300.8 | 76,185.8 | 84,981.0 | 94,791.6 | 105,734.8 |
| Inventories, % | 26.21 | 24.58 | 24.73 | 22.94 | 20.32 | 23.76 | 23.76 | 23.76 | 23.76 | 23.76 |
| Accounts Payable | 22,818.1 | 20,668.2 | 25,081.0 | 25,345.2 | 24,739.8 | 32,780.9 | 36,565.3 | 40,786.5 | 45,495.1 | 50,747.3 |
| Accounts Payable, % | 13.66 | 10.88 | 11.59 | 11.28 | 9.6 | 11.4 | 11.4 | 11.4 | 11.4 | 11.4 |
| Capital Expenditure | -10,000.1 | -8,189.2 | -7,011.5 | -11,828.9 | -13,493.0 | -13,821.3 | -15,416.9 | -17,196.7 | -19,182.0 | -21,396.5 |
| Capital Expenditure, % | -5.99 | -4.31 | -3.24 | -5.26 | -5.24 | -4.81 | -4.81 | -4.81 | -4.81 | -4.81 |
| Tax Rate, % | 27.72 | 27.72 | 27.72 | 27.72 | 27.72 | 27.72 | 27.72 | 27.72 | 27.72 | 27.72 |
| EBITAT | 16,811.1 | 25,113.8 | 25,824.3 | 28,543.1 | 41,764.9 | 36,848.9 | 41,102.9 | 45,848.1 | 51,141.0 | 57,044.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -45,434.5 | 27,931.9 | 26,436.9 | 24,574.6 | 29,130.8 | 20,883.0 | 30,876.3 | 34,440.8 | 38,416.9 | 42,851.9 |
| WACC, % | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 138,751.0 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 44,566 | |||||||||
| Terminal Value | 2,283,365 | |||||||||
| Present Terminal Value | 1,710,150 | |||||||||
| Enterprise Value | 1,848,901 | |||||||||
| Net Debt | -807 | |||||||||
| Equity Value | 1,849,708 | |||||||||
| Diluted Shares Outstanding, MM | 808 | |||||||||
| Equity Value Per Share | 2,289.25 |
What You Will Receive
- Accurate CIPLANS Financial Data: Features both historical and projected figures for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures to your needs.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Cipla’s potential future performance.
- User-Friendly Design: Crafted for industry professionals while remaining accessible to newcomers.
Key Features
- Real-Life CIPLANS Data: Pre-loaded with Cipla Limited's historical financial information and future growth projections.
- Fully Customizable Inputs: Tailor revenue growth, profit margins, WACC, tax rates, and capital expenditures to suit your analysis.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your entered parameters.
- Scenario Testing: Develop multiple forecasting scenarios to evaluate various valuation possibilities.
- User-Friendly Design: Intuitive and organized, suitable for both experts and newcomers.
How It Works
- Step 1: Download the Excel file for Cipla Limited (CIPLANS).
- Step 2: Examine the pre-filled financial data and forecasts for Cipla Limited (CIPLANS).
- Step 3: Adjust essential variables such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model being updated in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the findings for your investment strategies.
Why Opt for This Calculator?
- All-in-One Solution: Features DCF, WACC, and financial ratio analyses consolidated in a single tool.
- Flexible Inputs: Modify the yellow-highlighted cells to explore different scenarios.
- In-Depth Analysis: Automatically computes Cipla Limited's intrinsic value and Net Present Value.
- Pre-Loaded Information: Access to historical and projected data provides reliable starting points.
- High-Quality Standards: Perfect for financial analysts, investors, and business consultants alike.
Who Should Benefit from This Product?
- Pharmaceutical Students: Master drug valuation methods while utilizing real-world data.
- Researchers: Integrate industry-standard models into your academic studies or investigations.
- Investors: Validate your investment theories and evaluate valuation results for Cipla Limited (CIPLANS).
- Market Analysts: Enhance your efficiency with a ready-to-use, customizable DCF model.
- Entrepreneurs: Understand how major public pharmaceutical companies like Cipla are evaluated.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Cipla Limited (CIPLANS), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for the Weighted Average Cost of Capital (WACC), featuring key parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models presenting intrinsic value along with detailed calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to facilitate thorough analysis.
- Key Ratios: Comprehensive coverage of profitability, leverage, and efficiency ratios for Cipla Limited (CIPLANS).
- Dashboard and Charts: Visual representation of valuation outputs and assumptions for straightforward result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.